Financial Performance - Total revenue increased by 81% year-over-year, reaching $181.4 million in Q2 2025, compared to $100 million in Q2 2024[11] - Molecular Profiling Services revenue grew by 86% year-over-year, amounting to $162.9 million in Q2 2025, up from $87.7 million in Q2 2024[11] - Pharma R&D Services revenue increased by 49% year-over-year, reaching $18.5 million in Q2 2025, compared to $12.4 million in Q2 2024[11] - Clinical ASP improved by 52%, rising from $2,138 in Q2 2024 to $3,256 in Q2 2025[15] - Gross margin increased by 2,514 basis points year-over-year, reaching 62.7% in Q2 2025[15, 42] - Adjusted EBITDA turned positive, reaching $16.7 million in Q2 2025, compared to a loss of $50.9 million in Q2 2024[15, 34] - Free Cash Flow turned positive, reaching $5.9 million in Q2 2025, compared to a loss of $65.5 million in Q2 2024[15, 34] Operational Highlights - Clinical volume grew by 22%, with 50,032 clinical cases completed in Q2 2025[15] - The company's molecular dataset surpassed 900,000+ comprehensive tumor patient profiles, including over 529,000 Whole Exomes and 580,000 Whole Transcriptomes[15, 21] - Caris Assure ASP increased 58.7% year-over-year to $2,519 in Q2 2025[40] - MI Profile ASP increased 53.1% year-over-year to $3,379 in Q2 2025[40] Strategic Initiatives - The Partner Oncology Alliance (POA) expanded to 97 sites with over 1,100 publications[15, 23] - A landmark Caris Assure study was published, validating the single assay across the cancer care continuum[15, 26]

Clinical Trial Updates - Data from the ASPEN-06 trial highlights CD47 expression as a key predictive biomarker, demonstrating a compelling clinical response of evorpacept activity in HER2+ gastric cancer[12] - The Phase 2 ASPEN-Breast evorpacept trial design was updated to enable a CD47 and HER2 biomarker-driven strategy in a single-arm study[12] - Dose escalation was completed in the Sanofi-sponsored trial of evorpacept with SARCLISA® and dexamethasone in previously treated multiple myeloma, with Sanofi moving into dose optimization[12] - The first patient is anticipated to be enrolled in August in the phase 1 clinical trial of the novel EGFR-targeted antibody-drug conjugate (ADC), ALX2004[12] Financial Strategy - Focus on evorpacept in ASPEN-Breast and ALX2004, while pausing ASPEN-CRC, results in cash runway extended into Q1 2027[12] - The company had cash, cash equivalents, and investments of $84 million as of June 30, 2025[100] Upcoming Milestones - ASPEN-06 CD47 expression data update is expected in Q4 2025[12] - Initial safety data for ALX2004 is anticipated in 1H 2026[12] - ASPEN-breast interim data readout is expected in Q3 2026[12] ASPEN-06 Trial Results - In the ITT population, Evorpacept + TRP showed a 41% ORR compared to 27% in the TRP control arm[42] - In patients with HER2-positivity confirmed by fresh biopsy or ctDNA, evorpacept demonstrated a 49% ORR compared to 245% in control[45] - In patients with HER2+ and CD47-high gastric cancer (n=43), evorpacept + TRP had a 65% ORR versus 26% ORR for TRP[53] ASPEN-Breast Trial - In breast cancer patients with confirmed HER2-positivity, evorpacept + zanidatamab had a 56% confirmed ORR[63]

NASDAQ: SCWO Investor Presentation August 12, 2025 ©2025 374Water Inc. All Rights Reserved. This document and the information set forth herein are the property of 374Water. Clean & Sustainable Destruction of Organic Waste Second Quarter 2025 Strategic and Commercial Update and Financial Results Conference Call Cautionary Statement Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain "forward-looking statements" of 374Water Inc. ("374Water," "the ...

Zorevunersen for Dravet Syndrome - Stoke Therapeutics is developing zorevunersen as a potential disease-modifying medicine for Dravet syndrome [16] - Initial 70mg doses of zorevunersen demonstrated substantial and sustained reductions in convulsive seizure frequency [18] - Ongoing zorevunersen treatment showed substantial and durable reductions in major motor seizure frequency in OLE studies [21] - 36-month OLE data shows continuing improvements in cognition and behavior with zorevunersen treatment [56] - The EMPEROR Phase 3 study is designed to assess disease modification in Dravet syndrome with a dosing regimen of 2x70mg followed by 2x45mg over a 52-week treatment period [31, 32] - The EMPEROR Phase 3 study has dosed its first patient in August 2025 and anticipates data in 2H 2027, randomizing approximately 170 patients across ~70 global sites [35] STK-002 for Autosomal Dominant Optic Atrophy (ADOA) - Approximately 65-90% of ADOA cases are caused by mutations in one allele of the OPA1 gene, leading to haploinsufficiency [64] - Up to 46% of ADOA patients are registered as legally blind [65] - Preclinical findings support further development of STK-002, showing increased OPA1 protein and ATP-linked respiration [70] - A Phase 1 study of STK-002 in ADOA patients is underway in the UK, involving 21 patients aged ≥18 to <55 years receiving single ascending doses (0.1, 0.3, 0.5, & 0.7 mg/eye) [76]

Company Overview and Strategy - Mobile Infrastructure owns a diversified portfolio of parking assets primarily in the Midwest and Southwest and aims to improve revenue consistency and NOI margin through conversion from leased to managed contracts[6] - The company's strategic plan focuses on driving NOI growth through asset profile optimization, pivoting to management contracts, implementing an asset management approach, and exploring ancillary revenue opportunities like EV charging[14] - As of June 30, 2025, 29 out of 40 assets have been converted to management contracts, with plans to convert the remaining assets in 2026-2027, which is expected to accelerate revenue growth and cost savings[25] Financial Performance and Valuation - The company's Net Asset Value (NAV) is $7.25 per share, indicating a potentially attractive valuation compared to the higher replacement cost of its assets[6] - For the quarter ended June 30, 2025, managed property revenue was $7441 thousand, while base rental income was $1447 thousand, and percentage rental income was $104 thousand[49] - Net Operating Income (NOI) for the quarter ended June 30, 2025, was $5435 thousand, a decrease of 35% compared to $5633 thousand for the same period in 2024[49] - Adjusted EBITDA for the quarter ended June 30, 2025, was $3846 thousand, compared to $4074 thousand for the same period in 2024[50] Market and Acquisition Strategy - The U S parking industry generates approximately $131 billion in annual revenue, representing about 1% of the U S GDP[28] - The company has a $300 million pipeline of potential acquisitions and intends to become the acquirer of choice in the parking industry through its unique, tax-efficient acquisition program[6, 45]

Financial Performance - H&R Block's FY25 total revenue grew by 42% to $37610 million[12,40] - The company's FY25 EBITDA reached $976 million[13] a 14% increase compared to the previous year's $9632 million[40] - Adjusted earnings per share increased by 57% to $466[40] - H&R Block forecasts FY26 revenue between $3875 billion and $3895 billion and EBITDA between $1015 billion and $1035 billion[48] Capital Allocation - The company increased its quarterly dividend by 12%[14] - H&R Block has repurchased over 43% of its shares outstanding since 2016[16] - The company plans approximately $400 million in share repurchases[49] Business Segments - Small business revenue experienced double-digit growth[27] with overall revenue increasing 13% year-over-year[27] - Newly created Spruce accounts increased by approximately 40% in FY25[29] - Approximately 50% of FY25 deposit transactions originated from non-tax sources[30,32]

Company Highlights - Smart Sand has a total plant annual capacity of approximately 10 million tons [23, 50] - The CEO owns approximately 18% of the company, and insiders own approximately 36% [19, 105] - The company has repurchased approximately 62 million shares since January 2023 [19, 105] - Dividends of $010 per common share were paid in October 2024 and August 2025 [19, 105] Financial Performance - Q2 2025 sales volume was 1424 thousand tons [26] - Q2 2025 revenue was $858 million [28] - Q2 2025 contribution margin per ton was $1108 [29] - Q2 2025 adjusted EBITDA was $7751 thousand [29, 119] Logistics and Operations - The Oakdale facility has 243 million tons of reserves and a 40+ year reserve life [19] - The Ottawa facility has 127 million tons of reserves and a 75+ year reserve life [19] - The Blair facility has 114 million tons of reserves and a 35+ year reserve life [19]

Company Overview - NEXGEL creates custom hydrogel solutions and develops patented medical devices, custom/white label products, and OTC healthcare consumer products[7] - The company has agreements with multi-billion dollar corporations[9] - NEXGEL has one of two state-of-the-art manufacturing facilities in North America that can produce hydrogel transdermal products[14] - The facility has a total capacity of over 1.4 billion square inches of product per year[15] Strategic Partnerships - Cintas Corporation will distribute NEXGEL's SilverSeal wound care solution to its customers[41] - STADA Arzneimittel AG is partnering with NEXGEL to expand its OTC product portfolio, with their first joint product, Histasolv, generating over $20 million in annualized European revenue[42] - CG Converting and Packaging is the exclusive supplier of gel pads for AbbVie's Rapid Acoustic Pulse device, with AbbVie acquiring Soliton for $550 million in December 2021[43] Financial Performance - Q2 2025 revenue was $2.88 million, a 100% increase compared to $1.44 million for Q2 2024[50] - Q2 2025 gross profit was $1.26 million with a profit margin of 43.6%, compared to 20.3% in Q2 2024[50] - The company reiterates revenue guidance of $13 million for 2025 and expects to achieve positive EBITDA during the year[50] Acquisitions - Silly George Beauty Brand was acquired in May 2024 and has an annual run-rate of over $5 million[36] - Kenkoderm Skincare Line was acquired in December 2023 and is immediately accretive[40]

Company Overview - ClearPoint Neuro enables cell, gene, and device therapies by offering precise navigation to the brain and spine[6] - The company's platform includes clinical products for neurosurgeons and drug development services for BioPharma partners[6] - ClearPoint Neuro has built a complete drug delivery ecosystem over 15+ years[8] - The company has 100+ active global centers and 60+ partners across 20+ indications[8] Market Opportunity - The company estimates its current portfolio provides access to a ≈$500 million market opportunity[8] - ClearPoint Neuro sees a $10 billion potential diversified market[9] - Over 30 million people in the U S are estimated to suffer from severe and debilitating neurological disorders[10] - Neurological diseases cost Americans nearly $800 billion annually[10] Financial Performance - The company's 2024 revenue was $31.4 million[52] - As of June 30, 2025, the company had $41.5 million in cash and cash equivalents[52] - The company's gross margin is 60%[52] - The company's 2024 operational cash burn was ($9.0 million)[52]

Financial Performance - Telecom Argentina's 1H25 adjusted EBITDA reached $399 million, a 54% increase compared to 1H24[12] - The company reported a 30% EBITDA margin in 1H25, compared to 29.7% in 1H24[12, 28] - Telecom Argentina's 1H25 CAPEX totaled $359.336 million[81] - Telecom Argentina raised a total of approximately $2.6 billion in USD equivalent through various transactions[105] Telefónica Móviles Argentina (TMA) Acquisition - The acquisition of TMA contributed to a proforma revenue of $4.009 billion and EBITDA of $1.129 billion for FY24[24] - TMA's 1H25 figures include just four months of contribution to Telecom Argentina's consolidated results[24] - Actions are being taken to improve TMA's EBITDA margin, targeting an 11% margin as reported in 1H25[33] Operational Highlights - Personal Pay, Telecom Argentina's digital wallet, has onboarded over 4.2 million clients, representing a 44% year-over-year increase[12, 64] - Mobile ARPU evolution in US$ increased by 15% for TMA and 19% for TEO[48] - Broadband ARPU evolution in US$ increased by 12% for TMA and 22% for TEO[48] Debt Management - Successful issuance of Class 24 Notes for $800 million in May and a tap for $200 million in July, reducing the bond's average financing cost from 9.50% to 9.36%[12] - The company has a balanced debt maturity profile, with approximately 72% of debt in US dollars, RMB, and Guaraní[111] Regulatory and Environmental - Telecom Argentina submitted its comments to the CNDC regarding the June 19 technical opinion[37] - Telecom Argentina's near-term science-based targets have been approved, reinforcing the company's environmental commitments[115]